Answers are grounded in this paper and cite their sources.
• Although LIF expression in peripheral blood was not effective for early breast cancer diagnosis, it increased during treatment in patients with a good prognosis, particularly in the luminal tumor subtype, suggesting its potential as a prognostic marker. • LIF expression in blood showed moderate negative correlations with the markers HIF-1α and heparanase, both associated with poorer prognoses, reinforcing LIF's potential role in treatment response and prognosis evaluation. • Elevated LIF expression in the blood of breast cancer patients may reflect interactions within the tumor microenvironment, suggesting a protective role against uncontrolled proliferation, possibly mediated by immune response. • LIF expression was particularly relevant in monitoring patients with the luminal subtype of breast cancer, where LIF expression increased during treatment, in contrast to the HER2-enriched and triple-negative subtypes, where no such change was observed. Analysis of gene expression profiles in peripheral blood cells has been explored as an approach for early detection of breast cancer. Thus, we aimed to evaluate the diagnostic and prognostic potential of LIF expression in the peripheral blood of women with breast cancer. A total of 121 women over 18 years of age with breast cancer and 80 healthy women were included. Peripheral blood samples were collected from patients at diagnosis and during chemotherapy treatment, as well as samples from healthy women for comparison. LIF expression was evaluated by qPCR. LIF expression does not differ between patients and healthy women, ruling out its use as a liquid biopsy diagnostic tool for this disease. However, LIF expression increases during treatment in patients with positive progression and luminal tumor subtype, suggesting its potential as a prognostic marker. To reinforce this result, there was a negative correlation between LIF and HIF-1α and LIF and heparanase expression in blood, and LIF blood expression and a prognostic tumor score, all known markers associated with an unfavorable prognosis. An increase in LIF expression in patients with negative disease progression suggests its potential as a therapeutic response indicator, particularly for those with the luminal tumor subtype. The negative correlation between LIF, HIF-1α, and heparanase provides new insights into LIF's role in breast cancer progression, with potential clinical implications for treatment monitoring. Elevated LIF expression in blood samples may reflect its interaction in tumorigenesis, immune regulation, and the tumor microenvironment.
No takes yet. Share an insight, caveat, or question.
Penteado et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: